Give Catchy Heading Related To Trend/Driver With Numbers (Write full billion/million)

US DNA vaccine market was valued at $409.41 million in 2025 and is projected to reach $654.05 million by 2035, expanding at a CAGR of 4.9% over the forecast period from 2026 to 2035. The US DNA Vaccine segment is progressing rapidly as companies translate plasmid DNA platform technology into clinical and regulatory milestones. Continued investment in DNA vaccine constructs and delivery systems is expanding therapeutic and prophylactic options within the broader immunization landscape. Clinical advancement of candidates that leverage plasmid DNA design reflects strong scientific confidence in this modality’s potential to address diseases with unmet needs. These developments are enhancing US positioning in next?generation vaccine solutions and influencing strategic activity across both human and delivery technology segments.

Browse the full report description of “US DNA Vaccine Market Size, Share & Trends Analysis Report by Type (Animal DNA Vaccine, and Human DNA Vaccine), by Technology (Plasmid DNA Vaccines Technology, and Plasmid DNA Delivery Technology), by Application (Oncology, Infectious Diseases, and Others), Forecast Period 2026-2035” at https://www.omrglobal.com/industry-reports/us-dna-vaccines-market

In the first quarter of 2024, Inovio Pharmaceuticals, Inc. reported significant progress in its DNA vaccine pipeline. The company highlighted advancement of INO?3107, a DNA vaccine candidate targeting recurrent respiratory papillomatosis (RRP), with an anticipated regulatory pathway aimed at addressing a condition with limited effective therapies. The company also reaffirmed continued development of INO?3112 in combination with immuno?oncology agents. This clinical momentum aligns with broader official statistics showing sustained federal research investment and robust trial activity for DNA vaccine platforms within the US, reinforcing ongoing market development during 2024.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • Type
  • Technology
  • Application
• Competitive Landscape – Dynavax Technologies Corp., Inovio Pharmaceuticals, Inc., Johnson & Johnson, Merck & Co., Inc., Vaxart, Inc., among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

US DNA Vaccine Market Report Segment

By Type

• Animal DNA Vaccine
• Human DNA Vaccine

By Technology

• Plasmid DNA Vaccines Technology
• Plasmid DNA Delivery Technology

By Application

• Oncology
• Infectious Diseases
• Others

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/us-dna-vaccines-market